EGFR and non-small cell lung carcinoma: Four clinical studies, including ADJUVANT, EVEN, ADAURA, and EVIDENCE, examined the efficacy of postoperative adjuvant EGFR-TKI treatment in EGFR-mutant NSCLC, which provided clinicians with several useful informations, and changed the therapeutic modes of EGFR-TKI in the clinical setting to a certain extent.